Improved Survival of a HER2-Positive Metastatic Breast Cancer Patient Following a Personalized Peptide Immunization

Schönharting W, Roehnisch T, Manoochehri M, Christoph J, Sieger M, Nogueira M, Martos-Contreras MC, Kunz M (2023)

Publication Type: Journal article

Publication year: 2023

Journal

Vaccines MDPI

Book Volume: 11

Article Number: 1023

Journal Issue: 6

DOI: 10.3390/vaccines11061023

Abstract

Cancer neoantigens that arise from somatic mutations have emerged as important targets for personalized immunization. Here, we report an improved overall survival of a HER2-positive metastatic breast cancer patient using a bioinformatic-based personalized peptide immunization called BITAP (BioInformatic Tumor Address Peptides). The epitopes were predicted using our in-house bioinformatic pipeline, and the immunogenicity was tested by IFN-γ ELISPOT and intracellular cytokine staining assays. In total, a significant peptide-specific T-cell response was detected against 18 out of the 76 (≈24%) tested peptides. The patient’s follow-up by measuring serologic markers showed a significant reduction in the tumor marker levels following BITAP immunization. Along with standard treatment, the patient treated with the BITAP showed stable disease with a remarkably improved overall survival, and no serious treatment-related adverse effects. In conclusion, our findings suggest that BITAP immunization is feasible, and safe, and may induce tumor regressions in patients with HER2-positive subsets of breast cancer.

Involved external institutions

Precision Medicine and Cancer Research (PMCR GmbH) DE Germany (DE) Interdisziplinäres Onkologisches Zentrum München DE Germany (DE)

How to cite

APA:

Schönharting, W., Roehnisch, T., Manoochehri, M., Christoph, J., Sieger, M., Nogueira, M.,... Kunz, M. (2023). Improved Survival of a HER2-Positive Metastatic Breast Cancer Patient Following a Personalized Peptide Immunization. Vaccines, 11(6). https://doi.org/10.3390/vaccines11061023

MLA:

Schönharting, Wolfgang, et al. "Improved Survival of a HER2-Positive Metastatic Breast Cancer Patient Following a Personalized Peptide Immunization." Vaccines 11.6 (2023).

BibTeX: Download